| Symbol | IQV |
|---|---|
| Name | IQVIA HOLDINGS INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Services-Commercial Physical & Biological Research |
| Address | 2400 ELLIS ROAD, DURHAM, NC 27703 |
| Telephone | 919-998-2000 |
| Fax | — |
| — | |
| Website | https://www.iqvia.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001478242 |
| Description | IQVIA Holdings Inc is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The Technology & Analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business. Additional info from NASDAQ: |
(99% Neutral) IQVIA HOLDINGS INC. (IQV) Provides Update on jurisdiction for which such offer
Read more(99% Neutral) IQVIA HOLDINGS INC. (IQV) Provides Update on jurisdiction for which such offer
Read moreIQVIA - IQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities
Read moreIQVIA and Kexing Biopharm Expand Strategic Collaboration to Accelerate Global Biosimilar Development using AI-Enabled Capabilities
Read moreDirector Wims Morris Leslie 🟢 acquired 171 shares (1 derivative) of IQVIA HOLDINGS INC. (IQV) Transaction Date: May 07, 2026 | Filing ID: 033655
Read more